Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 5/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.89 |
| ▸ | AR | P10275 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 2/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 6/20 | 0.79 |
| ▸ | ESR1 | P03372 | 3/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.79 |
| ▸ | SHBG | P04278 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone Acetate SCHEMBL8038659 | 1.00 | CYP3A4 (0.89) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL11321479 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL14074495 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL1232662 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL37530 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL14577826 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL14360522 | 0.94 | CYP3A4 (1.00) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL16757740 | 0.91 | CYP3A4 (0.93) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL7091490 | 0.91 | PGR (0.79) | CYP3A4ABCB11PGRCYP2C19NR3C1 | |
| Norethindrone Acetate SCHEMBL28828333 | 0.90 | CYP3A4 (0.72) | CYP3A4ABCB11PGRCYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2422774-A1 | Pharmaceutical composition containing a tetrahydrofolic acid | Bayer Pharma Aktiengesellschaft (DE) | 2012-02-29 | — | — | EP | claimed |
| EP-2331067-A1 | PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2011018482-A1 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | WO | claimed |
| EP-2422774-A1 | Pharmaceutical composition containing a tetrahydrofolic acid | Bayer Pharma Aktiengesellschaft (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2358351-A1 | DRUG DELIVERY SYSTEM | Bayer Pharma Aktiengesellschaft (DE) | 2011-08-24 | — | — | EP | disclosed |
| EP-2331067-A1 | PROGESTIN-CONTAINING DRUG DELIVERY SYSTEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011018482-A1 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | WO | disclosed |
| US-20100021529-A1 | STEP-DOWN ESTROGEN REGIMEN FOR WOMEN RECEIVING ESTROGEN THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-0464150-A4 | SKIN PERMEATION ENHANCER COMPOSITIONS | — | 1993-04-14 | — | — | EP | disclosed |
| EP-0464150-A1 | SKIN PERMEATION ENHANCER COMPOSITIONS. | CYGNUS RESEARCH CORP (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5059426-A | Administering diethylene glycol monomethyl or monoethyl ether with an ester component; useful with steroids | CYGNUS THERAPEUTIC SYSTEMS (US) | 1991-10-22 | — | — | US | disclosed |
| WO-1990011064-A1 | SKIN PERMEATION ENHANCER COMPOSITIONS | CYGNUS RESEARCH CORPORATION (US) | 1990-10-04 | — | — | WO | disclosed |